Fox Run Management L.L.C. bought a new stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) during the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 1,679 shares of the medical equipment provider’s stock, valued at approximately $315,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. Hamilton Lane Advisors LLC increased its stake in ABIOMED by 50.8% during the 4th quarter. Hamilton Lane Advisors LLC now owns 23,241 shares of the medical equipment provider’s stock valued at $4,356,000 after buying an additional 7,827 shares during the period. Schwab Charles Investment Management Inc. increased its stake in ABIOMED by 7.3% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 137,552 shares of the medical equipment provider’s stock valued at $25,779,000 after buying an additional 9,370 shares during the period. Creative Planning increased its stake in ABIOMED by 50.1% during the 4th quarter. Creative Planning now owns 6,033 shares of the medical equipment provider’s stock valued at $1,131,000 after buying an additional 2,015 shares during the period. Bank of Montreal Can increased its stake in ABIOMED by 87.8% during the 4th quarter. Bank of Montreal Can now owns 5,051 shares of the medical equipment provider’s stock valued at $947,000 after buying an additional 2,362 shares during the period. Finally, Country Trust Bank increased its stake in ABIOMED by 11.5% during the 4th quarter. Country Trust Bank now owns 111,137 shares of the medical equipment provider’s stock valued at $20,828,000 after buying an additional 11,485 shares during the period. 90.52% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have commented on ABMD. Zacks Investment Research raised shares of ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 target price on the stock in a research note on Tuesday, November 7th. BidaskClub raised shares of ABIOMED from a “hold” rating to a “buy” rating in a research note on Thursday, January 11th. Leerink Swann lifted their price objective on shares of ABIOMED from $200.00 to $265.00 and gave the stock an “outperform” rating in a research note on Friday, January 19th. Piper Jaffray Companies lifted their price objective on shares of ABIOMED to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, October 26th. Finally, BTIG Research reaffirmed a “hold” rating on shares of ABIOMED in a research note on Sunday, October 29th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $210.50.

ABIOMED, Inc. (NASDAQ ABMD) opened at $238.89 on Friday. The stock has a market cap of $10,560.00, a P/E ratio of 117.68, a PEG ratio of 3.12 and a beta of 0.15. The company has a quick ratio of 5.20, a current ratio of 5.84 and a debt-to-equity ratio of 0.02. ABIOMED, Inc. has a 52 week low of $103.53 and a 52 week high of $239.10.

ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.38 by $0.16. The company had revenue of $132.80 million for the quarter, compared to analysts’ expectations of $131.18 million. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The business’s revenue was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS. research analysts expect that ABIOMED, Inc. will post 2.41 earnings per share for the current fiscal year.

In other news, Director Dorothy E. Puhy sold 6,364 shares of ABIOMED stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $179.08, for a total value of $1,139,665.12. Following the transaction, the director now directly owns 39,532 shares of the company’s stock, valued at $7,079,390.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Michael G. Howley sold 10,000 shares of ABIOMED stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the completion of the transaction, the vice president now directly owns 56,757 shares in the company, valued at $10,139,070.48. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Fox Run Management L.L.C. Takes Position in ABIOMED, Inc. (ABMD)” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://theolympiareport.com/2018/01/28/fox-run-management-l-l-c-takes-position-in-abiomed-inc-abmd.html.

ABIOMED Company Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.